EX-99.1 2 p74146exv99w1.htm EX-99.1 exv99w1
 

EXHIBIT 99.1
AMERICAN PACIFIC CORPORATION
Fiscal 2007 Third Quarter Financial Results
Contact: Dana Kelley – (702) 735-2200
E-mail: InvestorRelations@apfc.com
Website: www. apfc.com
AMERICAN PACIFIC REPORTS OPERATING PROFIT OF $14.2
MILLION FOR THE FIRST NINE MONTHS OF FISCAL 2007
LAS VEGAS, NEVADA, July 31, 2007 — American Pacific Corporation (NASDAQ: APFC) today reported financial results for its fiscal 2007 third quarter ended June 30, 2007.
We provide non-GAAP measures as a supplement to financial results based on GAAP. A reconciliation of the non-GAAP measures to the most directly comparable GAAP measures is included in the accompanying supplemental data.
FINANCIAL HIGHLIGHTS
Quarter Ended June 30, 2007 Compared to Quarter Ended June 30, 2006
  Revenues increased 2% to $43.7 million from $42.8 million.
  Operating income increased to $3.7 million compared to $1.7 million.
  Adjusted EBITDA improved to $8.7 million compared to $7.8 million.
  Diluted earnings per share from continuing operations was $0.08 compared to a diluted loss per share from continuing operations of ($0.12).
Nine Months Ended June 30, 2007 Compared to Nine Months Ended June 30, 2006
  Revenues increased 23% to $122.2 million from $99.1 million.
  Operating income increased to $14.2 million compared to an operating loss of ($0.5) million, which included environmental remediation charges of $2.8 million.
  Adjusted EBITDA improved to $29.2 million compared to $17.8 million.
  Diluted earnings per share from continuing operations was $0.18 compared to a diluted loss per share from continuing operations of ($0.58).
The current year nine-month period includes a charge of $0.21 per diluted share related to our refinancing activities in February 2007. The prior year nine-month period includes an environmental remediation charge of $0.24 per diluted share.
We acquired our Fine Chemicals segment, or AFC, effective November 30, 2005. Financial results for the first nine months of fiscal 2007 include nine months of contribution from AFC compared to seven months from AFC for the first nine months of fiscal 2006.
CONSOLIDATED RESULTS OF OPERATIONS
Revenues Revenues for our third quarter of fiscal 2007 increased 2% to $43.7 million primarily attributed to:
  An increase in revenues from our Fine Chemicals segment of $4.8 million, partially offset by a decrease in revenues from our Specialty Chemicals segment of $2.3 million due to the timing of Grade I AP sales within the fiscal years.
– more –
3770 HOWARD HUGHES PARKWAY SUITE 300 LAS VEGAS, NV 89109
PHONE (702) 735-2200 FAX (702) 735-4876
Exhibit 99.1 – pg. 1

 


 

For the nine months ended June 30, 2007, revenues increased 23% to $122.2 million attributed to:
  Nine months of revenue from our Fine Chemicals segment in the fiscal 2007 period compared to seven months of revenue from our Fine Chemicals segment in the fiscal 2006 period.
  Increases in Specialty Chemicals revenues were driven primarily by higher Grade I AP volume and average price in our fiscal 2007 period.
See further discussion under our Segment Highlights.
Cost of Revenues and Gross Margins – For our fiscal 2007 third quarter, cost of revenues was $30.4 million compared to $30.9 million for the prior year quarter. The consolidated gross margin percentage improved to 31% from 28% in the prior year quarter. For the nine months ended June 30, 2007, cost of revenues increased $9.4 million, or 13%, to $79.7 million from $70.3 million for the prior year period. The gross margin percentage was 35% compared to 29%.
One of the most significant factors that affects, and should continue to affect, the comparison of our consolidated gross margins from period to period is the change in product mix between our two larger segments. Our Specialty Chemicals segment typically has higher gross margins than AFC or our Fine Chemicals segment. Measured in terms of revenues, Specialty Chemicals accounted for 20% and 30% of our operations during the three months and nine months ended June 30, 2007, compared to 26% and 33% in the corresponding prior year periods. Conversely, AFC accounted for 70% and 58% of our operations during the three-month and nine-month periods ended June 30, 2007, compared to 60% and 50% in the corresponding prior year periods.
In addition, the following factors affect our consolidated gross margin comparisons:
  Specialty Chemicals gross margin percentage improved 15 points for the third quarter and nine points on a year-to-date basis.
  Fine Chemicals segment gross margins were consistent between the quarterly periods and improved five points on a year to date basis.
See further discussion under our Segment Highlights.
Operating Expenses – For our fiscal 2007 third quarter, operating expenses decreased $0.5 million to $9.7 million from $10.2 million in the third quarter of fiscal 2006. For the nine months ended June 30, 2007, operating expenses increased $1.8 million to $28.3 million from $26.5 million in the prior period primarily due to AFC operating expenses being included for nine months in the current year period compared to seven months in the prior year period. In addition, operating expenses for the periods reflect:
  A decrease of $1.1 million for the quarter and $2.4 million for the year-to-date period in amortization expense related to AFC intangible assets compared to the prior year periods.
  An increase of $0.3 million for the quarter and $1.8 million for the year-to-date period for incentive compensation due to improved performance in fiscal 2007.
SEGMENT HIGHLIGHTS
Specialty Chemicals Segment
Quarter Ended June 30, 2007 Compared to Quarter Ended June 30, 2006
  Revenues decreased 21% to $8.8 million from $11.1 million.
  Operating profit was $1.9 million, or 22% of revenues compared to $2.0 million, or 18% of revenues. Segment EBITDA was $3.2 million, or 37% of revenues, compared to $3.3 million, or 30% of revenues.
– more –
Exhibit 99.1 – pg. 2

 


 

Nine Months Ended June 30, 2007 Compared to Nine Months Ended June 30, 2006
  Revenues increased 14% to $36.7 million from $32.3 million.
  Operating profit was $11.8 million, or 32% of revenues compared to $8.9 million, or 28% of revenues.
  Segment EBITDA was $15.7 million, or 43% of revenues, compared to $12.8 million, or 40% of revenues.
Specialty Chemicals revenues decreased during our fiscal 2007 third quarter compared to the prior year quarter largely due to the timing of Grade I AP orders, primarily under the Minuteman Program. Revenues from Grade I AP experienced a net decrease, comprised of a 34% decrease in volume offset partially by a 5% increase in average price per pound compared to the prior year quarter. Specialty Chemicals revenues also reflect a $0.4 million increase in Halotron revenues and $0.4 million decrease in Sodium Azide revenues for the fiscal 2007 third quarter as compared to the prior year period.
On a year-to-date basis, Specialty Chemicals revenues have increased 14% driven primarily by Grade I AP sales which reported a 10% increase in average price per pound, as a result of custom orders, and a 10% increase in volume.
Grade I AP revenues are typically derived from relatively few large orders. As a result, quarterly comparisons can vary significantly depending on the timing of individual orders throughout the year. The variances in average price per pound are largely due to changes in product mix during periods presented, as certain blends of Grade I AP are sold at higher unit prices than others. Average price per pound may continue to fluctuate somewhat in future periods, dependent on product mix and volume.
Specialty Chemicals operating profit for the fiscal 2007 periods reflects:
  A 15 point increase in Specialty Chemicals gross margins for the fiscal 2007 third quarter and a five point increase for the year-to-date period primarily because the prior year third quarter included unusually high manufacturing overhead costs.
  Increases in operating losses from our Sodium Azide products due to lower volumes and continued investment in R&D activities.
  Increases in Specialty Chemicals operating expenses, primarily due to higher insurance and incentive compensation, which on a year-to date basis, increased $0.7 million and $0.3 million, respectively.
Fine Chemicals Segment
Quarter Ended June 30, 2007 Compared to Quarter Ended June 30, 2006
  Revenues were $30.7 million compared to revenues of $25.9 million.
  Operating profit was $5.0 million compared to $3.8 million.
  Segment EBITDA was $8.4 million, or 27% of revenue, compared to EBITDA of $8.2 million, or 32% of revenue.
Nine Months Ended June 30, 2007 Compared to Nine Months Ended June 30, 2006
  Revenues were $70.7 million compared to revenues(a) of $50.0 million and pro forma(b) revenues of $68.2 million.
  Operating profit was $10.8 million compared to operating profit(a) of $4.4 million.
  Segment EBITDA was $20.9 million, or 30% of revenue, compared to EBITDA(a) of $14.3 million, or 29% of revenue.
 
(a)   Revenues, operating profit and EBITDA for the prior year period reflect seven months of AFC operations from November 30, 2005.
 
(b)   Pro forma revenues assume that AFC was acquired effective October 1, 2005.
Fine Chemicals revenues for the third quarter increased $4.8 million versus the prior year third quarter. The increase is substantially due to sales associated with its largest oncology product. Revenues from antiviral products were relatively consistent between the quarterly periods, however, characterized by an
– more –
Exhibit 99.1 – pg. 3

 


 

increase from one antiviral product offset by declines in two other antiviral products. To have significant increases or decreases in any single product produced within a quarterly period is a normal result of production cycles. Typically, AFC runs a campaign of one product for several months then changes to another product. The cycles are determined based on customer delivery requirements and the most effective use of the facilities. In addition, during the fiscal 2007 third quarter, AFC shipped significant levels of an antiviral product which is recorded as deferred revenues as of June 30, 2007 because the customer acceptance period had not yet lapsed.
For the quarter ended June 30, 2007, operating profit improved $1.2 million. The improvement is primarily due to the additional gross margin contributed by the higher revenue volume for the fiscal 2007 third quarter. Increases in AFC operating expenses, primarily insurance and pension expense, were offset by a $1.1 million decrease in amortization expense.
On a year-to-date basis, Fine Chemicals revenues increased $20.7 million compared to the prior year period primarily due to the fiscal 2007 period including nine months of AFC operations compared to seven months of operations in the prior year period.
The increase in operating profit for the nine months ended June 30, 2007, reflects:
  The fiscal 2007 period including nine months of AFC operations compared to seven months of operations in the prior year period.
  A five point improvement in the gross margin percentage due to changes in product mix to include more R&D and oncology products in the fiscal 2007 period, as well as better absorption of manufacturing overheads due to the higher product volumes.
  A net increase in operating expenses of $2.6 million, with the most significant increases attributed to insurance, pension costs and incentive bonuses.
  A decrease in amortization expenses of $2.4 million.
Aerospace Equipment Segment
Quarter Ended June 30, 2007 Compared to Quarter Ended June 30, 2006
  Revenues decreased 21% to $4.1 million from $5.2 million.
  Operating profit was $0.3 million compared to $0.4 million.
Nine Months Ended June 30, 2007 Compared to Nine Months Ended June 30, 2006
  Revenues decreased 6% to $12.6 million from $13.4 million.
  Operating profit was $0.6 million compared to $0.8 million.
The decrease in revenues for both the fiscal 2007 third quarter and nine-month periods relate to the timing of orders from ISP’s largest customer. ISP completed production under a multi-year contract in May 2007. Production on the follow-on order begins in August 2007. As a result, revenues in the fiscal 2007 periods are reduced by the lag time between the orders.
For the nine months ended June 30, 2007, Aerospace Equipment gross margins have improved approximately three points largely due to the current period activity including more standard production thruster work compared to the prior year periods which included a greater volume of development activities. The higher gross margin contribution was offset by higher general and administrative cost, particularly personnel costs. As a result, operating profit margin for the fiscal 2007 periods was consistent with the prior year periods.
CAPITAL AND LIQUIDITY HIGHLIGHTS
Liquidity – As of June 30, 2007, we had cash balances of $21.9 million and no amounts drawn against our $20.0 million revolving credit line. In addition, we were in compliance with the various covenants contained in our credit facilities.
– more –
Exhibit 99.1 – pg. 4

 


 

Operating Cash Flows Cash flows from operating activities during the fiscal 2007 nine-month period improved by $18.8 million compared to the prior year nine-month period. Operating activities provided cash of $19.9 million for the fiscal 2007 nine-month period compared to $1.1 million for the prior year period.
Significant components of the change in cash flow from operating activities include:
  An increase in cash provided by Adjusted EBITDA of $11.4 million.
 
  A decrease in cash used to fund working capital increases of $4.6 million, excluding the effects in interest and income taxes.
 
  A decrease in cash used for interest payments of $1.3 million, including a payment of $0.4 million for the early payment of our second lien term loan in February 2007.
 
  A reduction in cash used for environmental remediation of $3.9 million.
 
  An increase in cash taxes paid of $0.8 million.
 
  Other increases in cash used for operating activities of $1.6 million.
Cash used to fund working capital decreased during the FY07 nine-month period because the increase in cash provided by deferred revenues and accounts receivable of $21.2 million exceed the increase in cash used to fund inventory, primarily at AFC, of $11.6 million and other increases in cash used for prepaid expenses, accounts payable and accrued expenses of $5.0 million. We consider these working capital changes to be routine and within the normal production cycle of our products. The production of certain fine chemical products requires a length of time that exceeds one quarter. Therefore, in any given quarter, work-in-progress inventory can increase or decrease significantly. Deferred revenues arise primarily because some of our AFC products are subject to customer acceptance periods. Revenue recognition is deferred from the date of shipment until the acceptance period lapses, which is generally occurs in the subsequent quarter. We expect that our working capital may vary normally by as much as $10.0 million from quarter to quarter.
Cash used for interest decreased primarily due to the timing of the interest payments. Our current debt instruments require semi-annual interest payments in February and August compared to the debt instruments in place during the prior year nine-month period which required interest payments at the end of each quarter. Cash used for environmental remediation decreased because during fiscal 2006 we were in the construction phase of the project compared to the lower cash requirements of the operating and maintenance phase in fiscal 2007.
Capital Expenditures – During the first nine months of fiscal 2007, we have spent $3.9 million in cash capital expenditures. This rate of expenditures is lower than the prior year period because during the prior year nine-month period we were actively involved in the construction of the new SMB facility at AFC. In addition, our rate of capital expenditure spending to date in fiscal 2007 is less than we expect for the full year. We anticipate that our capital expenditures will increase during our fiscal 2007 fourth quarter, consistent with the annual guidance provided below.
Financing Cash Flows – As previously disclosed, financing cash flows for the fiscal 2006 nine-month period primarily reflect debt issued in connection with our AFC acquisition. Financing cash for the fiscal 2007 nine-month period primarily reflect the refinance and repayment of debt issued in the prior year and the issuance of $110 million unsecured senior notes.
OUTLOOK
We are increasing our guidance for fiscal year 2007. For fiscal 2007, we expect revenues of $175 million, EBITDA of $40 million and operating profit, which is before interest and taxes, of $21 million. The increase in our guidance reflects strong operating performance from our Fine Chemicals segment and improved demand for Grade I AP from our Specialty Chemicals segment. We estimate capital expenditures for fiscal year 2007 will be approximately $10 million.
– more –
Exhibit 99.1 – pg. 5

 


 

INVESTOR TELECONFERENCE
We invite you to participate in a teleconference with our executive management covering the 2007 fiscal third quarter financial results. The investor teleconference will be held Tuesday July 31, 2007 at 1:30 p.m., Pacific Daylight Time. The teleconference will include a presentation by management followed by a question and answer session. The teleconference can be accessed by dialing (973) 582-2852 between 1:15 and 1:30 p.m., Pacific Daylight Time. Please reference conference ID# 9066835. As is our customary practice, a live webcast of the teleconference is being provided by Thomson Financial’s First Call Events. A link to the webcast and the press release is available at our website at www.apfc.com, and will be available for replay until our next quarterly investor teleconference.
RISK FACTORS/FORWARD-LOOKING STATEMENTS
The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including without limitation all statements regarding our beliefs about future demand for Grade I AP, our Fine Chemicals segment order and operations levels, our working capital changes and future variations, factors that will affect our cost of revenues and gross margins, and all statements in the “Outlook” section of this press release. Words such as “believes”, “anticipates”, “plans”, “expects”, “intend”, “will”, “goal” and similar expressions are intended to identify forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by the Company that any of its plans will be achieved. Actual results may differ materially from those set forth in the release due to risks and uncertainties inherent in the Company’s business. Factors that might cause such differences include, but are not limited to, the risk of any reduction or changes in NASA or U.S. government military spending, the loss of any one of our limited number of customers, the failure of continued appropriations by Congress for our customers’ existing or future U.S. government contracts, cost over-runs on our fixed price contracts, termination of the U.S. government contracts at its convenience, failure to comply with our customer’s specification and manufacturing instructions or timing and delivery requirements, schedule delays in our manufacturing processes, complex procurement regulations, environmental concerns, our substantial amount of debt, the restrictive debt covenants and the cost of servicing such debt, the ability to secure and maintain adequate liquidity to manage our operations, the hazardous nature of our product, the disruption of the supply of key raw materials, our inability to adapt to rapid technological changes and the other risks and uncertainties detailed in our filings with the Securities and Exchange Commission. Readers of this release are referred to our Annual Report on Form 10-K for the year ended September 30, 2006 and our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2007 and December 31, 2006 for further discussion of these and other factors that could affect future results. The forward-looking statements contained in this news release are made as of the date hereof and American Pacific assumes no obligation to update for actual results or to update the reasons why actual results could differ materially from those projected in the forward-looking statements. In addition, the operating results and cash flows for the three and nine-month periods ended June 30, 2007 are not necessarily indicative of the results that will be achieved for future periods.
ABOUT AMERICAN PACIFIC CORPORATION
American Pacific is a leading manufacturer of specialty and fine chemicals within its focused markets, as well as propulsion products sold to defense, aerospace and pharmaceutical end markets. Our products provide access to, and movement in, space via solid fuel and propulsion thrusters and represent the key active ingredient in drug applications such as HIV, epilepsy and cancer. We also produce specialty chemicals utilized in various applications such as fire extinguishing systems, as well as manufacture water treatment equipment. Our products are designed to meet customer specifications and often must meet certain governmental and regulatory approvals. Additional information about American Pacific can be obtained by visiting the Company’s web site at www.apfc.com.
– more –
Exhibit 99.1 – pg. 6

 


 

AMERICAN PACIFIC CORPORATION
Consolidated Statements of Operations
(Unaudited, Dollars in Thousands, Except per Share Amounts)
                                 
    Three Months Ended   Nine Months Ended
    June 30,   June 30,
    2007   2006   2007   2006
     
Revenues
  $ 43,723     $ 42,840     $ 122,200     $ 99,102  
Cost of Revenues
    30,358       30,931       79,716       70,288  
     
Gross Profit
    13,365       11,909       42,484       28,814  
Operating Expenses
    9,660       10,187       28,264       26,468  
Environmental Remediation Charges
                      2,800  
     
Operating Income (Loss)
    3,705       1,722       14,220       (454 )
Interest and Other Income
    181       55       365       978  
Interest Expense
    2,709       3,280       9,169       7,405  
Debt Repayment Charges
                2,714        
     
Income (Loss) from Continuing Operations before Income Tax
    1,177       (1,503 )     2,702       (6,881 )
Income Tax Expense (Benefit)
    571       (642 )     1,339       (2,624 )
     
Income (Loss) from Continuing Operations
    606       (861 )     1,363       (4,257 )
Loss from Discontinued Operations, Net of Tax
          (192 )           (439 )
     
Net Income (Loss)
  $ 606     $ (1,053 )   $ 1,363     $ (4,696 )
     
 
                               
Basic Earnings (Loss) Per Share:
                               
Income (Loss) from Continuing Operations
  $ 0.08     $ (0.12 )   $ 0.19     $ (0.58 )
Discontinued Operations, Net of Tax
          (0.02 )           (0.06 )
     
Net Income (Loss)
  $ 0.08     $ (0.14 )   $ 0.19     $ (0.64 )
     
 
                               
Diluted Earnings (Loss) Per Share:
                               
Income (Loss) from Continuing Operations
  $ 0.08     $ (0.12 )   $ 0.18     $ (0.58 )
Discontinued Operations, Net of Tax
          (0.02 )           (0.06 )
     
Net Income (Loss)
  $ 0.08     $ (0.14 )   $ 0.18     $ (0.64 )
     
 
                               
Weighted Average Shares Outstanding:
                               
Basic
    7,378,000       7,304,000       7,345,000       7,299,000  
Diluted
    7,523,000       7,304,000       7,439,000       7,299,000  
– more –
Exhibit 99.1 – 7

 


 

AMERICAN PACIFIC CORPORATION
Consolidated Balance Sheets
(Unaudited, Dollars in Thousands)
                 
    June 30,   September 30,
    2007   2006
     
ASSETS
               
Current Assets:
               
Cash and Cash Equivalents
  $ 21,899     $ 6,872  
Accounts Receivable
    20,574       19,474  
Notes Receivable
          7,510  
Inventories
    57,627       39,755  
Prepaid Expenses and Other Assets
    2,098       1,845  
Deferred Income Taxes
    1,887       1,887  
     
Total Current Assets
    104,085       77,343  
Property, Plant and Equipment, Net
    116,472       119,746  
Intangible Assets, Net
    7,398       14,237  
Deferred Income Taxes
    21,701       21,701  
Other Assets
    8,616       6,428  
     
TOTAL ASSETS
  $ 258,272     $ 239,455  
     
 
               
LIABILITIES AND SHAREHOLDERS’ EQUITY
               
Current Liabilities:
               
Accounts Payable
  $ 10,759     $ 11,158  
Accrued Liabilities
    9,914       11,257  
Employee Related Liabilities
    5,707       4,600  
Environmental Remediation Reserves
    565       1,631  
Deferred Revenues
    22,280       5,683  
Current Portion of Debt
    230       9,593  
     
Total Current Liabilities
    49,455       43,922  
Long-Term Debt
    110,423       97,771  
Environmental Remediation Reserves
    15,146       15,880  
Pension Obligations and Other Long-Term Liabilities
    9,088       9,998  
     
Total Liabilities
    184,112       167,571  
     
Commitments and Contingencies
               
Shareholders’ Equity
               
Preferred Stock — No par value; 3,000,000 authorized; none outstanding
           
Common Stock — $0.10 par value; 20,000,000 shares authorized, 9,443,541 and 9,359,041 issued
    942       933  
Capital in Excess of Par Value
    87,580       86,724  
Retained Earnings
    3,675       2,312  
Treasury Stock - 2,034,870 shares
    (16,982 )     (16,982 )
Accumulated Other Comprehensive Loss
    (1,055 )     (1,103 )
     
Total Shareholders’ Equity
    74,160       71,884  
     
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY
  $ 258,272     $ 239,455  
     
– more –
Exhibit 99.1 – -pg. 8

 


 

AMERICAN PACIFIC CORPORATION
Consolidated Statements of Cash Flow
(Unaudited, Dollars in Thousands)
                 
    Nine Months Ended
    June 30,
    2007   2006
     
Cash Flows from Operating Activities:
               
Net Income (Loss)
  $ 1,363     $ (4,696 )
Adjustments to Reconcile Net Income (Loss) to Net Cash Provided by Operating Activities:
               
Depreciation and amortization
    14,502       14,166  
Non-cash interest expense
    1,975       2,314  
Share-based compensation
    67       287  
Non-cash component of debt repayment charges
    2,309        
Gain on sale of assets
          (610 )
Changes in operating assets and liabilities:
               
Accounts receivable
    (1,055 )     (5,399 )
Inventories
    (17,872 )     (6,273 )
Prepaid expenses
    (253 )     (3,461 )
Accounts payable and accrued liabilities
    5,230       6,361  
Deferred revenues
    16,597       (284 )
Environmental remediation reserves
    (1,800 )     (2,857 )
Pension obligations, net
    (351 )     128  
Discontinued operations, net
          921  
Other
    (830 )     490  
     
Net Cash Provided by Operating Activities
    19,882       1,087  
     
 
               
Cash Flows from Investing Activities:
               
Acquisition of business and earnout adjustment
    (6,000 )     (108,462 )
Capital expenditures
    (3,930 )     (13,429 )
Proceeds from sale of assets
          2,395  
Discontinued operations, net
    7,510       (403 )
     
Net Cash Used by Investing Activities
    (2,420 )     (119,899 )
     
 
               
Cash Flows from Financing Activities:
               
Proceeds from the issuance of long-term debt
    110,000       85,000  
Payments of long-term debt
    (108,533 )     (496 )
Short-term borrowings, net
          4,000  
Debt issuance costs
    (4,677 )     (1,782 )
Issuances of common stock
    572       158  
Excess tax benefit from stock option exercises
    203        
Discontinued operations, net
          (92 )
     
Net Cash Provided (Used) by Financing Activities
    (2,435 )     86,788  
     
Net Change in Cash and Cash Equivalents
    15,027       (32,024 )
Cash and Cash Equivalents, Beginning of Period
    6,872       37,213  
     
Cash and Cash Equivalents, End of Period
  $ 21,899     $ 5,189  
     
– more –
Exhibit 99.1 – pg. 9

 


 

AMERICAN PACIFIC CORPORATION
Supplemental Data
(Unaudited, Dollars in Thousands)
                                 
    Three Months Ended   Nine Months Ended
    June 30,   June 30,
    2007   2006   2007   2006
     
Operating Segment Data:
                               
Revenues:
                               
Specialty Chemicals
  $ 8,780     $ 11,098     $ 36,702     $ 32,282  
Fine Chemicals
    30,736       25,889       70,693       49,992  
Aerospace Equipment
    4,119       5,232       12,560       13,366  
Other Businesses
    88       621       2,245       3,462  
     
Total Revenues
  $ 43,723     $ 42,840     $ 122,200     $ 99,102  
     
 
                               
Segment Operating Income:
                               
Specialty Chemicals
  $ 1,935     $ 1,983     $ 11,846     $ 8,935  
Fine Chemicals
    4,950       3,758       10,795       4,434  
Aerospace Equipment
    310       445       607       764  
Other Businesses
    (183 )     (456 )     564       215  
     
Total Segment Operating Income
    7,012       5,730       23,812       14,348  
Corporate Expenses
    (3,307 )     (4,008 )     (9,592 )     (12,002 )
Environmental Remediation Charges
                      (2,800 )
     
Operating Income (Loss)
  $ 3,705     $ 1,722     $ 14,220     $ (454 )
     
 
                               
Depreciation and Amortization:
                               
Specialty Chemicals
  $ 1,290       1,287     $ 3,858       3,849  
Fine Chemicals
    3,401       4,486       10,146       9,834  
Aerospace Equipment
    38       19       104       54  
Other Businesses
    3       3       9       9  
Corporate
    127       139       385       420  
     
Total Depreciation and Amortization
  $ 4,859     $ 5,934     $ 14,502     $ 14,166  
     
 
                               
Segment EBITDA (a):
                               
Specialty Chemicals
  $ 3,225     $ 3,270     $ 15,704     $ 12,784  
Fine Chemicals
    8,351       8,244       20,941       14,268  
Aerospace Equipment
    348       464       711       818  
Other Businesses
    (180 )     (453 )     573       224  
     
Total Segment EBITDA
    11,744       11,525       37,929       28,094  
Less: Corporate Expenses, Excluding Depreciation
    (3,180 )     (3,869 )     (9,207 )     (11,582 )
Plus: Share-based Compensation
          54       67       287  
Plus: Interest Income
    181       55       365       978  
     
Adjusted EBITDA (b)
  $ 8,745     $ 7,765     $ 29,154     $ 17,777  
     
 
                               
Reconciliation of Net Income (Loss) to Adjusted EBITDA (b):
                               
 
                               
Net Income (Loss)
  $ 606     $ (1,053 )   $ 1,363     $ (4,696 )
Add Back:
                               
Loss from Discontinued Operations
          192             439  
Income Tax Provision (Benefit)
    571       (642 )     1,339       (2,624 )
Interest Expense
    2,709       3,280       9,169       7,405  
Debt Repayment Charges
                2,714        
Depreciation and Amortization
    4,859       5,934       14,502       14,166  
Environmental Remediation Charges
                      2,800  
Share-based Compensation
          54       67       287  
     
Adjusted EBITDA
  $ 8,745     $ 7,765     $ 29,154     $ 17,777  
     
 
(a)   Segment EBITDA is defined as segment operating income plus depreciation and amortization.
 
(b)   Adjusted EBITDA is defined as net income (loss) before loss from discontinued operations, income taxes, interest expense, debt repayment charges, depreciation and amortization, environmental remediation charges, and share-based compensation.
Segment EBITDA and Adjusted EBITDA are not financial measures calculated in accordance with GAAP and should not be considered as an alternative to income from operations as performance measures. EBITDA is presented solely as a supplemental disclosure because management believes that it is a useful performance measure that is widely used within the industry. In addition, EBITDA is a significant measurement for covenant compliance under our credit facilities. EBITDA is not calculated in the same manner by all companies and, accordingly, may not be an appropriate measure for comparison.
-O-
Exhibit 99.1 – pg. 10